Skip to main content

Table 1 Characteristics of subjects

From: A randomised, double-blind, placebo-controlled trial of tropisetron in patients with schizophrenia

 

Placebo group

Tropisetron group

P value

Sex (M/F)

10/10

9/11

NSa

Age

35.15 ± 8.54

34.96 ± 6.82

NSb

Subtype

Disorganised 1

Disorganised 0

NSa

 

Catatonia 1

Catatonia 0

 
 

Paranoid 13

Paranoid 11

 
 

Undifferentiated 2

Undifferentiated 3

 
 

Residual 3

Residual 6

 

Duration of illness

9.79 ± 6.43

12 ± 8.67

NSb

Dose of risperidone

3.8 ± 1.58

4.03 ± 1.59

NSb

No. smoking

5 (25%)

6 (30%)

NSa

Full IQ

87.00 ± 16.80

87.68 ± 18.86

NSb

PANSS score

Positive: 11.8 ± 3.12

Positive: 11.85 ± 3.22

NSb

 

Negative: 18.45 ± 6.66

Negative: 18.95 ± 5.23

 
 

General: 34.3 ± 7.53

General: 33.75 ± 8.69

 
 

Total: 64.55 ± 15.17

Total: 64.55 ± 15.65

 

QLS total score

77.05 ± 15.8

72.2 ± 13.95

NSb

Rate of completion

17 (85%)

16 (80%)

NSa

Reason for dropout

Physical illness: 1

Non-adherence: 2

 
 

Worsening of illness: 1

Unknown: 1

 
 

Adverse effects: 1 (extrapyramidal signs)

Adverse effect: 1 (chest pain)

 
  1. Data show the mean ± SD.
  2. aχ2 test; bStudent t test.
  3. NS = not significant; PANSS = Positive and Negative Syndrome Scale; QLS = Quality of Life Scale.